Amylyx posts Phase 3 LUCIDITY presentation on avexitide for post-bariatric hypoglycemia
Reuters2026/08/18 13:18- Amylyx highlighted Phase 3 LUCIDITY topline data for avexitide in post-bariatric hypoglycemia, meeting the primary endpoint and all secondary endpoints.
- Primary endpoint showed a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo at Week 16 (p=0.000003).
- Trial enrolled 78 patients in a randomized, double-blind design, testing avexitide 90 mg once daily versus placebo over 16 weeks.
- Safety profile described as generally well tolerated, with no treatment-related serious adverse events; common events included diarrhea and injection-site reactions.
- Company outlined plans for an FDA NDA submission by end-2026, targeting a potential commercial launch in 2027 if cleared.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lazard paper warns global supply chains face O-ring-style single-point failures amid geopolitics
Andalan Perkasa Abadi says unaware of material information behind NASA share volatility
Massive Buyback Faces "Cold Reception"! U.S. Treasury Bond Purchase Plan Hits a Wall, Liquidity Tool Risks Becoming Ineffective
The US Treasury's expanded repo operations faced a record-low subscription ratio, highlighting a bottleneck in long-term bond market absorption, which may force officials to further cut issuance of the less liquid 20-year US Treasury bonds.
Crypto prices
More
